The company produces therapeutics designed to holistically enhance the gut microbiome
EnteroBiotix, a developer of microbial therapeutics that enhance the gut microbiome, has announced the closing of its $21.5m (£15.5m) series A financing round. The proceeds will be used to advance the company's microbiome drug pipeline and underpin its product development and manufacturing capabilities.
The financing was led by Thairm Bio and includes US-based investor Kineticos Ventures, joining existing investors including Scottish Enterprise and SIS Ventures.
Dr James McIlroy, CEO, EnteroBiotix, said: "This successful financing round is a strong endorsement of our pioneering microbiome approach. It gives significant momentum to our mission to transform the lives of patients through novel orally delivered medicinal products that enhance the gut microbiome. We are determined to change the standard of care for patients battling debilitating diseases associated with the microbiome."
Mark R. Bamforth, Thairm, said: "We are delighted to extend our backing of EnteroBiotix's exciting microbiome-based portfolio. We believe that its innovative approach, including end-to-end control of its supply chain to support clinical trials, could provide significant benefits across a range of diseases."
Frank Lis, President, Kineticos Ventures, said: "At Kineticos Ventures we back ambitious entrepreneurs that are advancing the boundaries of scientific research to improve patient outcomes. We were attracted to EnteroBiotix's innovative approach to reinstating gut microbiome diversity and function as it has global potential in multiple disease areas."
The company's approach is designed to address diseases by enhancing the diversity of the microbiome. It claims its product portfolio has potential applicability across multiple disease areas. In addition to advancing its product pipeline, the company plans to grow its headcount to around 50 as well as expanding its manufacturing and analytical capabilities.